首页> 外文期刊>Brazilian Journal of Pharmaceutical Sciences >Preparation and in vitro & in vivo evaluation of cephalexin matrix tablets
【24h】

Preparation and in vitro & in vivo evaluation of cephalexin matrix tablets

机译:头孢氨苄基质片剂的制备及体内外评价

获取原文
           

摘要

The purpose of the study is to develop cephalexin controlled-release matrix tablets by using lower proportions of release retardant polymer and to establish their in vitro & in vivo correlation. Tablets were compressed by incorporating polymers in a matrix form along with drug which prolong the drug release. Twelve formulations were prepared by mixing ethyl cellulose (EC) and hydroxypropyl methylcellulose (HPMC) (three different viscosity grades) in various proportions. F-1 to F-4 formulations were prepared by incorporating drug, HPMC K4M and ethyl cellulose in 100 : 5 : 5, 100 : 10 : 5, 100 : 15 : 5 and 100 : 20 : 5; similarly, F-5 to F-8 were prepared with HPMC K15M; and F-9 to F-12 were prepared with HPMC K100M using a wet granulation process maintained same proportions, along with drug and EC. Tablets were evaluated for their pre-compression and post-compression characteristics and they were found to be in limits. From the dissolution testing, F-4 showed 100.34% medicament release in 12 h. In vivo studies were conducted on rabbit and pharmacokinetic parameters of the optimized formulation were evaluated using HPLC method. It was found that matrix tablets showed increased t 1/2 and decreased K el . The design signified that the drug release rate from tablets was influenced by the small proportion (around 7% of a tablet weight) of polymer mixture and it controlled 100% medicament release upto 12 h effectively with the low grade viscosity of HPMC combination, with good in vitro & in vivo correlation.
机译:该研究的目的是通过使用较低比例的释放延迟聚合物来开发头孢氨苄控释基质片剂,并建立其体内外相关性。通过以基质形式掺入聚合物以及延长药物释放的药物来压制片剂。通过以各种比例混合乙基纤维素(EC)和羟丙基甲基纤维素(HPMC)(三种不同的粘度等级)来制备十二种配方。通过将药物,HPMC K4M和乙基纤维素以100∶5∶5、100∶10∶5、100∶15∶5和100∶20∶5的比例掺入来制备F-1至F-4制剂。同样,用HPMC K15M制备F-5至F-8。 F-9至F-12和HPMC K100M均采用湿法制粒工艺制备,并与药物和EC保持相同的比例。评价片剂的压缩前和压缩后特性,发现它们处于极限。从溶出度测试来看,F-4在12小时内显示100.34%的药物释放。在兔子上进行了体内研究,并使用HPLC方法评估了优化配方的药代动力学参数。发现基质片剂显示出t 1/2增加和Kel降低。该设计表明,片剂的药物释放速率受少量聚合物混合物(约占片剂重量的7%)的影响,在HPMC组合物的低粘度下,它可以有效控制100%的药物释放长达12小时,并且具有良好的体内外相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号